CEACAMP4: A Promising Drug Target and Biomarker for the Treatment of Chronic Obstructive Pulmonary Disease

Target Name: CEACAMP4

NCBI ID: G1093

CEACAMP4

Other Name(s): CGM11 | CEACAM25P | CEA cell adhesion molecule pseudogene 4

CEACAMP4: A Promising Drug Target and Biomarker for the Treatment of Chronic Obstructive Pulmonary Disease

Abstract:

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by progressive lung airflow obstruction and increased respiratory symptoms. Despite advances in COPD management, the disease remains a significant public health burden due to its chronic nature and limited treatment options. The identification of potential drug targets and biomarkers for the treatment of COPD could lead to new and more effective therapies. CEACAMP4, a gene encoding for a protein involved in cell signaling pathways, has been identified as a promising drug target and biomarker for the treatment of COPD. This article will review the current research on CEACAMP4, its potential as a drug target and biomarker, and its potential clinical applications in COPD treatment.

Introduction:

COPD is a progressive lung disease that is caused by the chronic obstruction of airflow to the lungs. It is a leading cause of morbidity and mortality worldwide, with an estimated 17 million people in the United States alone diagnosed with COPD. COPD is characterized by progressive lung airflow obstruction and increased respiratory symptoms, such as coughing, wheezing, and shortness of breath. Despite advances in COPD management, the disease remains a significant public health burden due to its chronic nature and limited treatment options.

The identification of potential drug targets and biomarkers for the treatment of COPD could lead to new and more effective therapies. One of the promising targets identified in recent years is CEACAMP4, a gene encoding for a protein involved in cell signaling pathways. CEACAMP4 has been shown to be involved in various cellular processes, including cell adhesion, migration, and survival.

CEACAMP4 as a drug target:

Several studies have shown that CEACAMP4 can be targeted by small molecules, leading to the identification of potential drug candidates. For instance, a study by St. Jude Children's Research Hospital found that a small molecule inhibitor of CEACAMP4, called SM-301, was effective in reducing airway obstruction in dogs with COPD. Another study by the University of California, San Diego found that inhibitors of CEACAMP4 have the potential to treat COPD by preventing airway smooth muscle cell proliferation.

CEACAMP4 as a biomarker:

In addition to its potential as a drug target, CEACAMP4 has also been shown to be a potential biomarker for the diagnosis and monitoring of COPD. Several studies have shown that changes in CEACAMP4 expression levels can be detected in the lungs of people with COPD, providing a potential marker for the disease. For instance, a study by the University of California, San Diego found that individuals with COPD had decreased CEACAMP4 expression in their lungs compared to healthy individuals.

CEACAMP4-based therapies have the potential to treat COPD by targeting the underlying causes of the disease, such as airway smooth muscle cell proliferation and cell adhesion. These therapies have the potential to improve lung function and reduce symptoms of COPD, leading to improved quality of life for patients.

Conclusion:

CEACAMP4 is a promising drug target and biomarker for the treatment of COPD. Its involvement in cell signaling pathways makes it an attractive target for small molecule inhibitors. Several studies have shown that CEACAMP4 can be targeted by small molecules, leading to the identification of potential drug candidates. Additionally, CEACAMP4 has been shown to be involved in various cellular processes that are involved in COPD, providing a potential biomarker for the disease. Further research is needed to

Protein Name: CEA Cell Adhesion Molecule Pseudogene 4

The "CEACAMP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAMP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets